Cargando…

Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation

Small cell esophageal carcinoma (SCEC) is a rare, undifferential type of cancer, with a high degree of malignancy and early systemic metastasis. Radio-chemotherapy and surgery have been used as the primary treatment strategies for SCEC, but they both result in poor prognosis. There is need to develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Weiwei, Zhang, Xiaoyan, Fang, Yu, He, Jia, Huang, Jingjing, Li, Shanqing, Ma, Tonghui, Li, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036436/ https://www.ncbi.nlm.nih.gov/pubmed/35480123 http://dx.doi.org/10.3389/fonc.2022.808801

Ejemplares similares

Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer
por: Papageorgiou, Georgios I., et al.
Publicado: (2021)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
por: Rizvi, Wajeeha, et al.
Publicado: (2017)

Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib
por: Yang, Jing-Xiao, et al.
Publicado: (2023)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer
por: Borja, Nicholas A., et al.
Publicado: (2023)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
por: Li, Caixia, et al.
Publicado: (2022)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
por: Zhang, Hui, et al.
Publicado: (2022)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

The ATM signaling network in development and disease
por: Stracker, Travis H., et al.
Publicado: (2013)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report
por: Chen, Zhujun, et al.
Publicado: (2023)

Gracillin Shows Potential Efficacy Against Non-Small Cell Lung Cancer Through Inhibiting the mTOR Pathway
por: Li, Yamei, et al.
Publicado: (2022)

Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients
por: Liang, Naixin, et al.
Publicado: (2021)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer
por: Zeng, Bing, et al.
Publicado: (2021)

Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
por: Hirayama, Yukiyoshi, et al.
Publicado: (2022)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Small Extracellular Vesicles in the Development, Diagnosis, and Possible Therapeutic Application of Esophageal Squamous Cell Carcinoma
por: Zhao, Zheng, et al.
Publicado: (2021)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022)

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
por: Wang, Junhui, et al.
Publicado: (2023)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress
por: Han, Tao, et al.
Publicado: (2022)

A Satisfactory Financial Position
Publicado: (1916)

Are Our Dental Organizations Satisfactory?
Publicado: (1894)

An Externally-Validated Dynamic Nomogram Based on Clinicopathological Characteristics for Evaluating the Risk of Lymph Node Metastasis in Small-Size Non-small Cell Lung Cancer
por: Wu, Yijun, et al.
Publicado: (2020)

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
por: Ma, Tiantian, et al.
Publicado: (2022)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Case Report: Next-Generation Sequencing Reveals Tumor Origin in a Female Patient With Brain Metastases
por: Li, Qun, et al.
Publicado: (2021)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
por: Herath, Nirmitha I., et al.
Publicado: (2019)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kohm8f0n6jp6gj7r9j2u0ivjpe